Digbi Health Capitalizes on GLP-1 Market Shift, Expands GLP Compass™, and Introduces Employer-Subsidized and Cash-Pay Pathways via Digbi RxFund™
/MOUNTAIN VIEW, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Digbi Health, the leader in precision biology for metabolic and digestive health, today announced a major expansion of its GLP-1 Compass™platform with the launch of Digbi RxFund™. This industry-first financial innovation provides employers and employees with streamlined, subsidized, and cash-pay pathways for obesity care, ensuring high-quality clinical oversight outside of traditional, opaque pharmacy benefit designs.
"The conventional PBM-based GLP-1 model forces employers into an 'all-or-nothing' choice: absorb unsustainable financial risk or face employee dissatisfaction," said Ranjan Sinha, Founder and CEO of Digbi Health. "Eli Lilly’s direct-to-employer move validates that the market is shifting toward alternatives outside of traditional PBM models. Digbi RxFund™ gives employers a smarter path—combining flexible funding with precision metabolic care to ensure GLP-1 use is effective, appropriate, and sustainable.”